Member of the Association of American Physicians
Mark J. Ratain mainly focuses on Pharmacology, Internal medicine, Pharmacokinetics, Toxicity and Gastroenterology. His Pharmacology research includes elements of Irinotecan, Glucuronidation and Pharmacogenetics. His Internal medicine research is multidisciplinary, incorporating elements of Endocrinology, Surgery and Oncology.
Within one scientific family, he focuses on topics pertaining to Glucuronide under Pharmacokinetics, and may sometimes address concerns connected to Diarrhea. His studies in Toxicity integrate themes in fields like Immunology and Chemotherapy. His research integrates issues of Recombinant DNA, Renal function, Hairy cell leukemia, Leukemia and Bone marrow in his study of Gastroenterology.
His primary areas of study are Internal medicine, Pharmacology, Pharmacokinetics, Oncology and Toxicity. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Surgery. He has researched Pharmacology in several fields, including Irinotecan and Pharmacogenetics.
He combines subjects such as Pharmacogenomics and Bioinformatics with his study of Pharmacogenetics. The concepts of his Pharmacokinetics study are interwoven with issues in Metabolite, Endocrinology and Glucuronide. His Oncology study integrates concerns from other disciplines, such as Bevacizumab, Colorectal cancer, Genome-wide association study and Breast cancer.
Mark J. Ratain spends much of his time researching Internal medicine, Oncology, Pharmacogenomics, Pharmacology and Pharmacogenetics. His research combines Gastroenterology and Internal medicine. His Oncology research incorporates elements of Cetuximab, Clinical trial, Proportional hazards model, Bevacizumab and Single-nucleotide polymorphism.
His research on Pharmacogenomics also deals with topics like
Mark J. Ratain focuses on Internal medicine, Pharmacogenomics, Pharmacology, Clinical trial and Pharmacogenetics. Mark J. Ratain interconnects Gastroenterology and Oncology in the investigation of issues within Internal medicine. The Pharmacology study combines topics in areas such as Clinical endpoint and Intensive care medicine.
His research in Clinical trial intersects with topics in Interquartile range, Medical physics and Response Evaluation Criteria in Solid Tumors. His Pharmacogenetics research incorporates themes from Guideline, Drug, Genome-wide association study and Bioinformatics. His research investigates the connection with Genome-wide association study and areas like Genetic association which intersect with concerns in Toxicity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw.
The New England Journal of Medicine (2010)
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty.
Journal of Clinical Oncology (2006)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Federico Innocenti;Samir D. Undevia;Lalitha Iyer;Pei Xian Chen.
Journal of Clinical Oncology (2004)
Tumour heterogeneity in the clinic
Philippe L. Bedard;Aaron R. Hansen;Aaron R. Hansen;Mark J. Ratain;Lillian L. Siu;Lillian L. Siu.
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Lalitha Iyer;Christopher D. King;Peter F. Whitington;Mitchell D. Green.
Journal of Clinical Investigation (1998)
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
L Iyer;S Das;L Janisch;M Wen.
Pharmacogenomics Journal (2002)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T Eisen;T Ahmad;K T Flaherty;M Gore.
British Journal of Cancer (2006)
Perceptions of cancer patients and their physicians involved in phase I trials.
Christopher Daugherty;Mark J. Ratain;Eugene Grochowski;Carol Stocking.
Journal of Clinical Oncology (1995)
Metabolic Fate of Irinotecan in Humans: Correlation of Glucuronidation with Diarrhea
Elora Gupta;Timothy M. Lestingi;Rosemarie Mick;Jacqueline Ramirez.
Cancer Research (1994)
Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
Razelle Kurzrock;Steven I. Sherman;Douglas W. Ball;Arlene A. Forastiere.
Journal of Clinical Oncology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: